Toll Free: 1-888-928-9744

Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 49 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016', provides in depth analysis on Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1)
- The report reviews Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) Overview 6 Therapeutics Development 7 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Stage of Development 7 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Therapy Area 8 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Indication 9 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Companies 12 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development 18 C4X Discovery Holdings PLC 18 Eisai Co., Ltd. 19 Hager Biosciences, LLC 20 Heptares Therapeutics Limited 21 Merck & Co., Inc. 22 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles 23 DORA-12 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 EORA-101 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HTL-6641 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 lemborexant - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Dormant Projects 32 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products 33 Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Featured News & Press Releases 34 May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 34 Feb 03, 2015: Merck's Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 34 Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 35 Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 36 Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 36 Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia 38 May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 39 May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 39 Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 40 Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 40 Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 41 Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 41 Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 43 Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 45 Jun 09, 2010: Merck Announces Phase IIb Study Results Of Investigational Insomnia Therapy Drug MK-4305 45 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17 Pipeline by C4X Discovery Holdings PLC, H1 2016 18 Pipeline by Eisai Co., Ltd., H1 2016 19 Pipeline by Hager Biosciences, LLC, H1 2016 20 Pipeline by Heptares Therapeutics Limited, H1 2016 21 Pipeline by Merck & Co., Inc., H1 2016 22 Dormant Projects, H1 2016 32 Discontinued Products, H1 2016 33


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 17

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify